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Objective: Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor substrate-1
expression, inhibited corneal neovascularization in a previous dose-ﬁnding phase II study. We aimed to
conﬁrm these results in a phase III study and investigated a potential clinical beneﬁt on visual acuity (VA), quality
of life (QoL), and need for transplantation.
Design: Multicenter, double-masked, randomized, placebo-controlled phase III study.
Participants: Analysis of 69 patients with keratitis-related progressive corneal neovascularization random-
ized to aganirsen (34 patients) or placebo (35 patients). Patients applied aganirsen eye drops (86 mg/day/eye) or
placebo twice daily for 90 days and were followed up to day 180.
Main Outcome Measures: The primary end point was VA. Secondary end points included area of pathologic
corneal neovascularization, need for transplantation, risk of graft rejection, and QoL.
Results: Althoughnosigniﬁcantdifferences inVAscoresbetweengroupswereobserved,aganirsensigniﬁcantly
reduced the relativecorneal neovascularizationareaafter 90daysby26.20% (P¼0.014). This improvementpersisted
after 180 days (26.67%, P ¼ 0.012). Aganirsen tended to lower the transplantation need in the intent-to-treat (ITT)
population at day 180 (P¼ 0.087). In patientswith viral keratitis and central neovascularization, a signiﬁcant reduction
in transplantation needwasachieved (P¼0.048).Nosigniﬁcant differencesbetweengroupswereobserved in the risk
of graft rejection. However, aganirsen tended to decrease this risk in patients with traumatic/viral keratitis (P¼ 0.162)
at day 90. The QoL analyses revealed a signiﬁcant improvement with aganirsen in composite and near activity
subscores (P¼ 0.039 and 0.026, respectively) at day 90 in the per protocol population. Ocular and treatment-related
treatment-emergent adverse events (TEAEs) were reported in a lower percentage with aganirsen compared with
placebo. Only 3 serious TEAEs (2 with aganirsen and 1 with placebo) were considered treatment-related.
Conclusions: This ﬁrst phase III study on a topical inhibitor of corneal angiogenesis showed that aganirsen
eye drops signiﬁcantly inhibited corneal neovascularization in patients with keratitis. The need for transplantation
was signiﬁcantly reduced in patients with viral keratitis and central neovascularization. Topical application of
aganirsen was safe and well tolerated. Ophthalmology 2014;121:1683-1692 ª 2014 by the American Academy of
Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).Penetrating corneal transplantation has a relatively high
success rate due to conditions that favor anterior cham-
bereassociated immune deviation and corneal immune
privilege.1 Multiple mechanisms maintain this privilege,
including the bloodeeye barrier, the lack of blood and
lymphatic vessels in the normal cornea (corneal angiogenic
privilege), the relative paucity of mature antigen-presenting
cells in the central cornea, the presence of immune- 2014 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). Published by Elsevier Inc.modulatory factors in ocular ﬂuids, and the constitutive
expression of CD95L (Fas ligand) within the eye.2 However,
the principal anatomic and biological feature of the cornea
determining its immunologic privilege is its avascularity,2,3
but this privilege can be eroded by inﬂammation and
trauma.4
Pathologic corneal angiogenesis in vascularized high-risk
beds exposes the graft to immune effector cells, and1683http://dx.doi.org/10.1016/j.ophtha.2014.03.038
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antigen-presenting cells and antigenic material from the
graft to regional lymph nodes, inducing alloimmunization
and subsequently high rates of graft rejection.2,5 A recent
meta-analysis conﬁrmed the known association between the
presence of pathologic corneal neovessels and the increased
risk of graft rejection. In fact, the risk of graft rejection
increased with the number of corneal quadrants being
affected by corneal neovessels.6,7 Consequently, an expert
panel recently declared a high unmet medical need for a
topical inhibitor of corneal angiogenesis.8
Engagement of insulin receptor substrate-1 (IRS-1) proteins
has been shown to be a crucial step in themechanism leading to
angiogenesis,9 and overexpression of IRS-1 has been found in
corneal neovascularization.10 Aganirsen (GS-101) is an
antisense oligonucleotide that inhibits IRS-1 mRNA expres-
sion. In preclinical studies, it dose-dependently inhibited IRS-1
expression and in vitro angiogenesis.9,11 There was also a
reduction in vascular endothelial growth factor (VEGF)-A and
the proinﬂammatory cytokine interleukin-1b mRNA expres-
sion.10 Aganirsen has an Orphan Drug designation from
the European Regulatory Authorities for the prevention of
corneal graft rejection via the management of corneal
neovascularization, a well-established risk factor for rejec-
tion.12 Administered as a painless topical application,
aganirsen represents a new strategy for inhibition and
regression of active ocular angiogenesis. The interim analysis
of a phase IIb study previously showed that there was a
decrease of 23% in the neovascular area in patients receiving
aganirsen at 86 mg/day (P ¼ 0.0047) compared with
placebo.13 Although not subjected to a similar interim
analysis, the mid-treatment data on visual acuity (VA) sug-
gested an improvement in patients receiving active treatment.13
The phase III clinical study reported in this article (the I-
CAN [Inhibition of CorneAl Neovascularization] study) is
the ﬁrst phase III study on a topical antiangiogenic agent for
use at the ocular surface and the cornea. It was primarily
aimed at conﬁrming the encouraging results seen for aga-
nirsen on corneal neovascularization in the phase II analysis.
It also investigated the effect of a topical angiogenic in-
hibitor on VA, need for subsequent transplantation, and
quality of life (QoL). One underlying hypothesis was to
examine whether an antiangiogenic therapy concomitant to
an antiviral/antibacterial therapy (used as primary preven-
tion) could inﬂuence or even decrease the need for subse-
quent corneal transplantation. This would be a novel
therapeutic concept and would have great socioeconomic
and medical implications.Methods
Study Objectives
The overall objectives were to ﬁrst conﬁrm the inhibitory effect of
aganirsen on corneal neovascularization in a placebo-controlled
study in patients who have keratitis or keratouveitis of bacterial,
viral, or traumatic origin, and potentially requiring a corneal
transplantation. This study also aimed at investigating a possible
correlation with VA as the main clinical beneﬁt. Other clinical
beneﬁts were investigated, including QoL, need for transplantation,1684and risk of graft rejection after potential future transplantation. The
safety and tolerability of aganirsen also were assessed.
Patients
Included patients had keratitis or keratouveitis of bacterial, viral
(e.g., herpes), or traumatic (e.g., alkali burns) origin. To be eligible
for inclusion, patients had to show evidence of progressive stromal
neovascularization documented during a minimum period of 1
week (1 month for patients recruited in French centers) and a
maximum of 2 months with corneal vessels reaching out for at least
2.5 mm from the limbus or reaching the corneal center. This was
assessed using a standardized semiquantitative method on at least 2
photographs of the cornea and validated by a Centralized Reading
Center (Felix Bock and Claus Cursiefen, Corneal Angiogenesis
Laboratory, University Erlangen-Nürnberg, Germany).14 At
inclusion, participants also had a VA score >20/200 and <20/20.
Institutional review board/ethics committee approvals were
obtained for each of the participating centers. Patients provided
written informed consent, and the study was performed according
to the Declaration of Helsinki and the International Conference on
Harmonization Good Clinical Practice guidelines. This study was
registered under the following number in the EudraCT database:
2008-005388-33, with the protocol code number GS101-P3-CG.
Study Design
This multicenter, double-masked, randomized study compared
aganirsen eye drops with placebo in 2 parallel groups and was
performed in 10 centers in 3 European countries (Germany,
Switzerland, and France). After validation of progressive corneal
neovascularization by the Centralized Reading Center, 2 subgroups
of patients were predeﬁned: patients with central neovascularization
(i.e., with vascularization extending beyond 2.5 mm from the limbal
arcade and reaching the central 4 mm of the cornea) and patients
with peripheral neovascularization (i.e., with vascularization
extending beyond 2.5 mm from the limbal arcade, but not extending
into the central 4 mm of the cornea). The neovascularization status
was used as a stratiﬁcation factor when randomizing patients to the
treatment (aganirsen or placebo) groups.
Randomized patients were instructed to apply 1 drop of aga-
nirsen at 0.86 mg/ml (43 mg/drop, i.e., 86 mg/day) or placebo (0.9%
saline) in the affected eye twice daily (in the morning and evening)
for 90 days. In cases of bilateral lesions, only the worst affected eye
was treated. In this study, concomitant medications were avoided,
but investigators were permitted to prescribe treatments as deemed
necessary. Although other antiangiogenic treatments were pro-
hibited during the study, patients were allowed to continue with
topical steroids, antibiotics, acyclovir, or cyclosporine as long as
the dose remained stable for the study duration and was in accor-
dance with center practice and local guidelines.
Efﬁcacy and safety variables were assessed at day 1 (baseline),
day 30, day 90 (end of study treatment), and day 180 (follow-up).
For patients recruited in French centers, an extra visit was per-
formed at day 7 for assessing safety.
Efﬁcacy Assessments
As stipulated by the Regulatory Authorities, the primary efﬁcacy
end point was VA at day 90, and this variable was assessed using
the standardized Early Treatment Diabetic Retinopathy Study
method.15e17 The secondary end points included the relative and
absolute changes in area of corneal neovascularization from
baseline (the relative change was the main efﬁcacy criterion for this
end point), the extent of neovascularization (by corneal quadrant
for stromal or epithelial vessels), the QoL evaluation, the need for
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transplantation, all evaluated at day 90.
As mentioned for the patients’ inclusion, measurements of the
area of corneal neovascularization were evaluated by the stan-
dardized semiquantitative method of computerized morphometry.14
The need for transplantation was assessed by rating the index of
need for penetrating keratoplasty as high, medium, or low, and
the risk of graft rejection after potential future transplantation was
evaluated following a risk proﬁle established according to the
Collaborative Corneal Transplantation Study data18 and Australian
Graft Registry.19 The QoL was assessed using the National Eye
Institute Visual Functioning Questionnaire-25 (Version 2000).20,21
These efﬁcacy criteria also were evaluated at day 180, and efﬁ-
cacy was assessed at day 90 and day 180 after ocular examination:
This examination included intraocular pressure measurement; ex-
amination of ocular tissues, such as cornea, iris, lens, and vitreous;
evaluation of corneal sensitivity using the noncontact corneal aes-
thesiometer method; and assessment of the presence of ulcerations
and punctuations after ﬂuorescein staining.
Patient compliance was assessed by the number of used and
unused single doses of study treatment in relation to the duration of
treatment. In addition, compliance with using at least 1 vial per day
was considered. The patient was considered noncompliant if the
total number of vials used þ2 was strictly inferior to the number of
days between the ﬁrst medication administration and the date of
visit scheduled at day 90.
Safety Assessments
Adverse events were monitored from the time of informed consent
to 3 months after treatment ended. Standard clinical laboratory
safety analyses, including hematology, biochemistry, and urinaly-
sis, were performed at day 1 and day 90, and physical examination
and vital signs were monitored at all visits. Severity of any toler-
ability parameters, that is, itching, redness, burning sensation,
foreign body sensation, blurred vision, and eye watering, were
assessed at all visits by the patient using a Visual Analogue Scale
(VAS) ranging from 0 to 100 mm. In addition, the investigator and
patient collaborated to score the severity of the symptom according
to the following scale: 0 ¼ absent, 1 ¼ mild, 2 ¼ moderate, and
3 ¼ severe.
Image Analysis
Pictures of the cornea were taken for inclusion at visit 1 (pre-
screening), visit 2 (screening), visit 3 (randomization/inclusion), visit
4 (day 303), visit 5 (day 907), and visit 6 (day 18015) at the
Centralized Reading Center (Felix Bock and Claus Cursiefen,
Corneal Angiogenesis Laboratory, University Erlangen-Nürnberg,
Germany). The standardized conditions and technical methods for
assessing corneal neovascularization have been described.14 Blinded
analyses of the photographs of the cornea were performed by
semiquantitative measurements and computerized morphometry
using image analysis software based on grey ﬁlter sampling
(Cell
ˇ
f; Olympus Soft Imaging Solutions GmbH, Münster,
Germany). Brieﬂy, after contrast and shading optimization of each
image, a region of interest was determined along the limbus. The
vascularized area (expressed as a percentage) was then calculated
by threshold setting and normalized to the total region of interest.
Progression in corneal neovascularization was deﬁned as
vascularized area at a time point strictly superior to vascularized
area at baseline.
Statistical Analysis
All statistical analyses were performed using SAS version 9.3
(SAS Inc, Cary, NC). Comparisons between treatment groups inprimary end point and secondary end points were 2-sided, and the
signiﬁcance level was set to a ¼ 0.050. The secondary analyses
were performed for exploratory purposes. The P values of sec-
ondary analyses were not corrected for multiple testing and so
should be viewed as nominal.
Chi-square or Fisher exact tests were performed on categoric
variables. Logistic models were used for secondary ordered efﬁ-
cacy parameters, including the need for transplantation and risk of
graft rejection. The “need for transplantation” was recorded as a
binary variable, where 0 ¼ low and 1 ¼ medium, high. The “risk of
graft rejection” was recorded as a binary variable, where 0 ¼ low,
very low, none, and 1 ¼ medium, high, very high. Odds ratios for
need for transplantation and risk of graft rejection calculated via
logistic model were adjusted for type of neovascularization (cen-
tral/peripheral). Baseline value of the binary parameter was added
into the model as other covariate. For continuous variables, analy-
sis of covariance (ANCOVA) was performed on efﬁcacy criteria.
Evolution of the relative changes in area of neovascularization
from baseline to day 180 was analyzed using a mixed-effect model
with patient identity as a random effect, with treatment, type of
neovascularization (central/peripheral), visit, interaction between
visit and treatment, and baseline value as ﬁxed effects.
Five populations were deﬁned: the screened population, the
randomized population (all patients randomized to study treat-
ment), the intention-to-treat (ITT) population (all randomized pa-
tients who had at least 1 post-baseline VA assessment), the per
protocol (PP) population (all ITT patients who did not have any
major protocol deviations), and the safety population (all ran-
domized patients who had at least 1 dose of study treatment). The
ITT population was the primary efﬁcacy population.
Analyses of 4 efﬁcacy variables (VA, relative change in area of
neovascularization from baseline, need for transplantation, and risk
of graft rejection) were performed for 2 subgroups of patients.
First, the ITT population was subdivided according to the type of
neovascularization (i.e., central and peripheral) and the origin of
keratitis or keratouveitis (i.e., bacterial, traumatic/viral, and viral).Results
Study Population
Study participation was from May 2009 to February 2013. Of 228
subjects screened, 99 were includedd49 in the aganirsen group
and 50 in the placebo groupdfrom 10 centers in Switzerland,
France, and Germany (Table 1). Those 99 patients were retained
for the safety population, but 30 (15 from each group) were
excluded from the ITT population because they did not meet the
criterion for evidence of progressive neovascularization and 2
patients were withdrawn after randomization, both from the
aganirsen group, because of an adverse event before day 90 (1
patient) and loss to follow-up at day 180 (1 patient). No patients
from the placebo group were withdrawn from the study (Table 1).
There were a total of 22 major protocol violations leading to
exclusion from the PP population: The most common violation
was the day 90 visit being performed after day 907 or 10 days
after the last study treatment.
Patients were well matched in both treatment groups in the ITT
and safety populations (Table 2). The most common cause of
keratitis or keratouveitis was traumatic in the aganirsen group
(44.1%) and viral in the placebo group (57.1%) (Table 2):
Comparison of keratitis origin between the treatment groups was
close to signiﬁcance (nominal P value ¼ 0.053, chi-square test).
No major differences were found at baseline between the 2 groups
in vessel typesdepithelial or stromaldin the 4 corneal quadrants
(data not shown), VA, need for transplantation, or risk of graft1685
Table 1. Disposition of Patients and Analysis Sets
All Randomized Treated Patients N (%) Patients Using Aganirsen N (%) Patients Using Placebo N (%)
Included patients 99 (100) 49 (100) 50 (100)
ITT population 69 (69.7) 34 (69.4) 35 (70)
Central neovascularization* 22 (22.2) 11 (22.4) 11 (22)
Peripheral neovascularizationy 47 (47.5) 23 (46.9) 24 (48)
Randomized patients withdrawn
from the study
2 (2) 2 (4.1) -
AE 1 (1) 1 (1) -
Lost to follow-up 1 (1) 1 (1) -
PP population 47 (47.5) 19 (38.8) 28 (56)
Safety population 99 (100) 49 (100) 50 (100)
AE ¼ adverse event; ITT ¼ intention-to-treat; PP ¼ per protocol.
*Deﬁned as vascularization extending beyond 2.5 mm from the limbal arcade and reaching the central 4 mm of the cornea.
yDeﬁned as vascularization extending beyond 2.5 mm from the limbal arcade, but not extending into the central 4 mm of the cornea.
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with 95.9% in the aganirsen group and 100.0% in the placebo
group using at least 1 vial per day (data not shown).
Primary Efﬁcacy End Point: Visual Acuity
Aganirsen did not statistically improve absolute VA value at day
90 compared with placebo in the ITT population (Table 3). Similar
results were obtained for the PP population. Statistical analysis
showed no inﬂuence of the following 4 factorsdtype of
neovascularization (central/peripheral), study center, age at
baseline, and genderdon the absolute VA values at day 90 (data
not shown).
Further analyses of this end point were performed on subgroups
according to the origin of keratitis (bacterial, traumatic/viral, andTable 2. Patient Demographics and Baseline Ch
All Patients N [ 6
Age (yrs)
Mean (SD) 51.3 (14.08)
Median 52.0
Min; max 18; 81
Sex
Female (%) 26 (37.7)
Male (%) 43 (62.3)
Ethnicity
Caucasian (%) 69 (100.0)
Origin of keratitis or keratouveitis*
Traumatic (%) 27 (39.1)
Bacteria and other microorganisms (%) 13 (18.8)
Viral (herpetic) (%) 30 (43.5)
Need for transplantationy
High/medium (%) 36 (52.1)
Low (%) 33 (47.8)
Risk of graft rejectiony
Medium/high/very high 45 (65.2)
None/very low/low 24 (34.8)
VA
Mean (SD) 53.67 (22.656)
Median 56.00
Min; max 10.0; 90.0
ITT ¼ intention-to-treat; SD ¼ standard deviation; VA ¼ visual acuity.
*One patient had >1 origin of keratitis or keratouveitis.
yAs assessed by the investigators.
1686viral) and the type of neovascularization (central and peripheral).
No signiﬁcant effect of aganirsen was observed on VA in the
subgroups (data not shown).
Secondary Efﬁcacy End Points
Corneal Neovascularization. The relative change in area of
corneal neovascularization from baseline to day 90 was the main
secondary efﬁcacy end point. Aganirsen signiﬁcantly improved the
relative area of corneal neovascularization after 3 months of
treatment (day 90) at a daily dose of 86 mg: a signiﬁcant
improvement of 26.0% was observed between baseline and day 90
with aganirsen compared with placebo (nominal P value ¼ 0.041)
(Fig 1, Table 4). Furthermore, a signiﬁcant improvement of
26.20% in the relative area of corneal neovascularization alsoaracteristics in Intention-to-Treat Population
9 Aganirsen N [ 34 Placebo N [ 35
48.7 (15.98) 53.8 (11.63)
49.5 54.0
18; 81 26; 75
13 (38.2) 13 (37.1)
21 (61.8) 22 (62.9)
34 (100.0) 35 (100.0)
15 (44.1) 12 (34.3)
9 (26.5) 4 (11.4)
10 (29.4) 20 (57.1)
16 (47.0) 20 (57.1)
18 (52.9) 15 (42.9)
22 (64.7) 23 (65.7)
12 (35.3) 12 (34.3)
55.32 (21.990) 52.06 (23.492)
58.00 52.00
12.0; 85.0 10.0; 90.0
Table 3. Absolute Visual Acuity Values at Day 90 in Intention-
to-Treat Population
All Patients
N [ 69
Aganirsen
N [ 34
Placebo
N [ 35
Absolute value
Mean (SD) 53.43 (26.851) 55.06 (25.605) 51.86 (28.291)
Median 58.00 55.50 58.00
Min; max 0.0; 100.0 0.0; 100.0 0.0; 92.0
ANCOVA,
P ¼ 0.982
Estimated
value
54.30 54.21
95% CI 48.09e60.51 47.99e60.42
ANCOVA ¼ analysis of covariance; CI ¼ conﬁdence interval; SD ¼
standard deviation.
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(nominal P value ¼ 0.016), indicating a persisting inhibitory
effect of aganirsen 3 months after treatment discontinuation (Fig
1, Table 4). The results were not inﬂuenced by the baseline data
or the type of neovascularization (peripheral or central) (data
not shown). Further analysis of the relative area of corneal
neovascularization using a mixed-effect model showed differ-
ences of 26.20% at day 90 (nominal P value ¼ 0.014) and 26.67%
at day 180 (nominal P value ¼ 0.012), in favor of aganirsen (data
not shown).
Statistical analyses by ANCOVA of the absolute changes in area
of corneal neovascularization from baseline showed a difference of
1.12% (95% conﬁdence interval [CI], 2.46 to 0.23) in favor of
aganirsen (nominal P value ¼ 0.143) at day 90 (data not shown).
However, the comparison of this secondary end point between
treatmentswas close to signiﬁcance at day 180: a difference of 1.14%
(95% CI, 2.37 to 0.10) in favor of aganirsen with nominal P
value ¼ 0.050 was observed at this time point (data not shown).
Further analyses by subgroups (origin of keratitis and type of
neovascularization) conﬁrmed the results obtained in the overall
ITT population: in each analyzed subgroup, there was a signiﬁcant
reduction (nominal P value <0.05) in the relative area of corneal
neovascularization with aganirsen at both day 90 and day 180 (data
not shown).Figure 1. Typical photographs (top) with corresponding morphometric analyse
herpetic viral keratitis before treatment (A) and after 90 days (B) and 180 days (
pathologic corneal neovessels.Extent of Neovascularization. No relevant differences between
aganirsen and placebo treatments in the extent of epithelial vessels
were observed in any corneal quadrants (data not shown). For the
extent of stromal vessels, no relevant differences between treat-
ments were observed in the nasal inferior or the temporal quadrant
(data not shown). However, an ANCOVA analysis at day 90
showed a signiﬁcant difference of 1.56 mm (95% CI, 0.21e2.91)
in favor of placebo in the nasal superior quadrant (nominal
P value ¼ 0.021, data not shown), although the analysis was
performed on imbalanced groups because of missing data (9
patients in the aganirsen group and 20 patients in the placebo
group).
Need for Transplantation. No relevant differences between the
aganirsen and placebo groups were observed in the need for
transplantation at day 90 in the overall ITT (Table 5). However, at
day 180, this difference was close to signiﬁcance (nominal P
value ¼ 0.087, chi-square test). The percentage of patients with
a low need for transplantation was higher in the aganirsen group
than in the placebo group (Table 5).
Further analyses showed that in the subgroup with viral origin of
keratitis, the percentage of patients with a low need for trans-
plantation at day 180 was numerically higher in the aganirsen group
than in the placebo group (nominal P value ¼ 0.121, chi-square
test) (Table 6). Similar results were obtained in the subgroup of
patients with central neovascularization (nominal P value ¼
0.170, chi-square test) (Table 6). When analyzing the need for
transplantation in patients with keratitis of viral origin and with
central neovascularization, results showed that aganirsen treatment
signiﬁcantly decreased the need for transplantation at both day 90
(nominal P value ¼ 0.048, data not shown) and day 180
(nominal P value ¼ 0.048, Fisher exact test) (Table 6).
Risk of Graft Rejection. No relevant differences between the
aganirsen and placebo groups were observed in the risk of graft
rejection at day 90 or day 180 in the overall ITT population
(nominal P values were 0.346 and 0.482, respectively, chi-square
test) (Table 5). However, by using a logistic model, the inﬂuence
of the type of neovascularization (central or peripheral) on risk
of rejection (high/medium vs. low) at day 90 in the ITT
population was close to signiﬁcance (nominal P value ¼ 0.072,
data not shown).
Analysis of the subgroup of patients with keratitis of traumatic/
viral origin revealed a trend toward a lower risk of graft rejection at
day 90 in favor of aganirsen (nominal P value ¼ 0.162, chi-squares (bottom) of a patient with progressive corneal neovascularization due to
C) of aganirsen treatment. Note the signiﬁcant reduction in area covered by
1687
Table 4. Relative Changes in Area of Corneal Neovascularization at Day 90 and Day 180 in Intention-to-Treat Population
All Patients N [ 69 Aganirsen N [ 34 Placebo N [ 35
Relative change from baseline at day 90 (%)
N 68 33 35
Mean (SD) 3.84 (47.849) 9.62 (29.291) 16.54 (57.984)
Median 0.67 6.77 7.06
Min; max 81.7; 189.7 76.4; 50.3 81.7; 189.7
ANCOVA, nominal P ¼ 0.041
Estimated relative change at day 90 (%) 11.48 14.52
95% CI 28.35 to 5.40 1.79 to 30.33
Relative change from baseline at day 180 (%)
N 68 33 35
Mean (SD) 2.82 (45.265) 10.88 (35.664) 15.75 (49.862)
Median 3.73 16.58 14.11
Min; max 87.3; 137.0 81.7; 66.3 87.3; 137.0
ANCOVA, nominal P ¼ 0.016
Estimated relative change at day 180 (%) 10.36 15.84
95% CI 26.21 to 5.48 0.52e31.15
ANCOVA ¼ analysis of covariance; CI ¼ conﬁdence interval; SD ¼ standard deviation.
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in the subgroup of patients with central neovascularization
(nominal P value ¼ 0.201, chi-square test) (Table 7).
Quality of Life. The National Eye Institute Visual Functioning
Questionnaire-25 questionnaire used to evaluate the effect on QoL
consisted of an overall composite score and 12 subscores assessing
the following aspects: general health, general vision, ocular pain,
near activities, distant activities, social functioning, mental health,
role difﬁculties, dependency, driving, color vision, and peripheral
vision. Although no relevant differences between aganirsen and
placebo groups were observed in the QoL questionnaire composite
score at day 90 in the ITT population, the PP population showed
after ANCOVA analysis a signiﬁcant improvement of 2.21 (95%
CI, 2.74 to 7.16) in the composite score with aganirsen at day 90
compared with placebo (nominal P value ¼ 0.039, data not
shown).
Analyses of QoL subscores in the PP population showed a
signiﬁcant improvement of 9.96 (95% CI, 3.00e16.91) in near
activities visual function with aganirsen compared with placebo atTable 5. Frequencies for Need for Transplantation and Risk of Graft R
All Patients N [ 69
Need for transplantation
Day 90
N 68
High/medium (%) 37 (54.4)
Low (%) 31 (45.6)
Day 180
N 66
High/medium (%) 36 (54.5)
Low (%) 30 (45.5)
Risk of graft rejection
Day 90
N 68
Medium/high/very high (%) 45 (66.2)
Low/very low/none (%) 23 (33.8)
Day 180
N 66
Medium/high/very high (%) 40 (60.6)
Low/very low/none (%) 26 (39.4)
1688day 90 (nominal P value ¼ 0.026), although this was not conﬁrmed
in the ITT population (data not shown). No relevant differences
between the groups were observed in composite score or subscores
of the QoL questionnaire at day 180 in the ITT population.
Complete Ophthalmic Evaluation. No relevant differences
were observed between the 2 groups in the absolute values of
intraocular pressure; corneal sensitivity; presence of ulcerations or
punctuations after ﬂuorescein staining analysis; status of lens, iris,
and vitreous; or the presence of cataracts at day 90 and day 180 in
the ITT population (data not shown).
Safety. Similar numbers of treatment-emergent adverse events
(TEAEs) were observed in both groups, and of these, ocular
TEAEs considered treatment-related represented 11.1% and 18.4%
in the aganirsen and placebo groups, respectively (Table 8). Most
TEAEs, including ocular TEAEs, were of mild or moderate
severity, and there was no evidence of increased incidence of
severe TEAEdocular or otherwisedin either treatment group.
None of the ocular TEAEs in the treated eye were reported in
more than 3 patients in either group. In the aganirsen group, theejection at Day 90 and Day 180 in Intention-to-Treat Population
Aganirsen N [ 34 Placebo N [ 35 P Values
33 35
17 (51.5) 20 (57.1) 0.641
16 (48.5) 15 (42.9)
32 34
14 (43.8) 22 (64.7) 0.087
18 (56.3) 12 (35.3)
33 35
20 (60.6) 25 (71.4) 0.346
13 (39.4) 10 (28.6)
32 34
18 (56.3) 22 (64.7) 0.482
14 (43.8) 12 (35.3)
Table 6. Frequencies for Need for Transplantation at Day 180 in Subgroups
All Patients N [ 69 Aganirsen N [ 34 Placebo N [ 35 P Values
Bacterial origin of keratitis
N 13 9 4
High/medium (%) 4 (30.8) 2 (22.2) 2 (50.0) 0.317
Low (%) 9 (69.2) 7 (77.8) 2 (50.0)
Traumatic/viral origin of keratitis
N 56 25 31
High/medium (%) 35 (62.5) 14 (56.0) 21 (67.7) 0.367
Low (%) 21 (37.5) 11 (44.0) 10 (32.3)
Viral origin of keratitis
N 30 10 20
High/medium (%) 15 (50.0) 3 (30.0) 12 (60.0) 0.121
Low (%) 15 (50.0) 7 (70.0) 8 (40.0)
Central neovascularization
N 22 11 11
High/medium (%) 15 (68.2) 6 (54.5) 9 (81.8) 0.170
Low (%) 7 (31.8) 5 (45.5) 2 (18.2)
Peripheral neovascularization
N 47 23 24
High/medium (%) 24 (51.1) 10 (43.5) 14 (58.3) 0.308
Low (%) 23 (48.9) 13 (56.5) 10 (41.7)
Viral origin of keratitis/central neovascularization
N 9 4 5
High/medium (%) 6 (66.7) 1 (25.0) 5 (100.0) 0.048
Low (%) 3 (33.3) 3 (75.0) -
Cursiefen et al  Aganirsen Inhibits Keratitis-Induced Corneal Neovascularizationmost frequently reported ocular TEAEs in the treated eye were
ulcerative keratitis and hordeolum (each reported in 2 patients,
4.1%). In the placebo group, they were conjunctivitis (3 patients,
6.0%), ulcerative keratitis, eye allergy, eye irritation, eye pain, eye
pruritus, and suture removal (each reported in 2 patients, 4.0%). All
the other ocular TEAEs in the treated eye were reported in no more
than 1 patient in each group.
Among the treatment-related ocular TEAEs, there was an
increased incidence of 2 eventsdeye pain and eye pruritusdin the
placebo group (2 patients, 4.0%, vs. none of the patients treated
with aganirsen).Table 7. Frequencies for Risk of Graft
All Patients N [ 69
Bacterial origin of keratitis
N 13
Medium/high/very high (%) 4 (30.8)
Low/very low/none (%) 9 (69.2)
Traumatic/viral origin of keratitis
N 56
Medium/high/very high (%) 41 (73.2)
Low/very low/none (%) 15 (26.8)
Viral origin of keratitis
N 30
Medium/high/very high (%) 21 (70.0)
Low/very low/none (%) 9 (30.0)
Central neovascularization
N 22
Medium/high/very high (%) 11 (50.0)
Low/very low/none (%) 11 (50.0)
Peripheral neovascularization
N 47
Medium/high/very high (%) 34 (72.3%)
Low/very low/none (%) 13 (27.7)Among the 26 treatment-emergent serious adverse events
(SAEs), there were 12 ocular SAEs, which were reported in a lower
percentage of patients treated with aganirsen (5 events in 3 patients,
6.1%) than with placebo (7 events in 6 patients, 12.0%). Only 3
treatment-emergent SAEs were considered to be related to treat-
ment: corneal degeneration and corneal disorder, both reported in 1
patient treated with aganirsen, and ocular neoplasm, reported in 1
patient treated with placebo. There were no other signiﬁcant
TEAEs and no deaths.
In regard to ocular tolerability, the highest mean VAS scores
(standard deviation) at baseline were obtained for the itemRejection at Day 90 in Subgroups
Aganirsen N [ 34 Placebo N [ 35 P Values
9 4
4 (44.4) - 0.109
5 (55.6) 4 (100.0)
25 31
16 (64.0) 25 (80.6) 0.162
9 (36.0) 6 (19.4)
10 20
6 (60.0) 15 (75.0) 0.398
4 (40.0) 5 (25.0)
11 11
4 (36.4) 7 (63.6) 0.201
7 (63.6) 4 (36.4)
23 24
16 (69.6) 18 (75.0) 0.677
7 (30.4) 6 (25.0)
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Table 8. Treatment-Emergent Adverse Events in Safety Population
All Patients N [ 99 Aganirsen N [ 49 Placebo N [ 50
n AEs n (%) Patients n AEs n (%) Patients n AEs n (%) Patients
All TEAEs
Any TEAE 190 74 (74.7) 90 36 (73.5) 100 38 (76.0)
Any treatment-related TEAE 20 11 (11.1) 7 4 (8.2) 13 7 (14.0)
Any TEAE leading to treatment discontinuation 5 3 (3.0) 3 2 (4.1) 2 1 (2.0)
Any severe TEAE 12 9 (9.1) 6 5 (10.2) 6 4 (8.0)
Any SAE 26 19 (19.2) 15 9 (18.4) 11 10 (20.0)
All ocular TEAEs diagnosed in the treated eye
Any ocular TEAE 60 39 (39.4) 20 16 (32.7) 40 23 (46.0)
Any treatment-related ocular TEAE 18 11 (11.1) 5 4 (8.2) 13 7 (14.0)
Any ocular TEAE leading to treatment discontinuation 4 2 (2.0) 2 1 (2.0) 2 1 (2.0)
Any severe ocular TEAE 6 6 (6.1) 3 3 (6.1) 3 3 (6.0)
Any ocular SAE 12 9 (9.1) 5 3 (6.1) 7 6 (12.0)
AE ¼ adverse event; SAE ¼ serious adverse event; TEAE ¼ treatment-emergent adverse event.
Ophthalmology Volume 121, Number 9, September 2014“blurred vision”: 37.9 (33.6) in the aganirsen group and 46.8
(31.4) in the placebo group, on a scale of 100 (data not shown).
No differences were found between treatments at any time point
regarding any of the VAS scores of the ocular tolerability items,
except foreign body sensation for which the mean score (standard
deviation) at day 180 was signiﬁcantly lower in the aganirsen
group (11.817.6) than in the placebo group (22.330.7) (nominal
P value ¼ 0.040) (data not shown).
Consistent with these ﬁndings, the severity of the symptoms
assessed during the study showed no difference between treatments
at any time point. No safety concerns were raised after assessment
of laboratory safety tests, vital signs, or physical examination.Discussion
The main aims of this study were (1) to conﬁrm the anti-
angiogenic and angio-regressive effect of topical aganirsen
treatment on progressive corneal neovascularization seen in the
interim analysis of the phase II study13 and (2) to investigate a
potential effect on VA, need for transplantation, and QoL as
clinical beneﬁts for the patient. Selection of VA as the
primary end point was a requirement from the Regulatory
Authorities because it has been used as a measure of efﬁcacy
in other ophthalmic studies on pathologies affecting the retina,
such as macular degeneration and diabetic retinopathy.22e24
This was to our knowledge the ﬁrst time that VA was used as
a primary end point in a study that included patients with a
pathology affecting the cornea.
In our study, we did not observe a positive effect of aga-
nirsen on VA compared with placebo. This ﬁnding was
consistent with a recently published systematic review of 11
studies that showed only weak evidence to support the hy-
pothesis that in patients with pathologic corneal neo-
vascularization, a treatment-related reduction of active corneal
neovascularization was associated with an increase in VA.25
Therefore, VA may not be the most appropriate primary end
point in a clinical study investigating ocular indications
associated with corneal neovascularization.26 This issue
also had been raised by a Consensus Conference on
Indications for and Treatment Modalities in Corneal1690Neovascularization.8 This weak association may be because
pathologic corneal neovessels lower VA not only by their
presence within the cornea itself but also by inducing
secondary effects in the corneal stroma, including edema,
lipid keratopathy, and bleeding.
Conﬁrming previously published results,13 our study
showed that aganirsen signiﬁcantly reduced the relative
area of corneal neovascularization by 26.20% after 3
months of treatment at a daily dose of 86 mg compared
with placebo. Furthermore, 3 months after treatment
discontinuation, an improvement of 26.67% in the relative
area of corneal neovascularization could still be observed
in the aganirsen group. The persisting inhibitory effect of
aganirsen may be explained by the anti-inﬂammatory ac-
tivity of aganirsen, complementing its antiangiogenic effect.
Indeed, in preclinical studies, daily aganirsen dosing has
been shown to reduce corneal angiogenesis and proin-
ﬂammatory cytokine production.9 In ocular pathologies,
inﬂammation and angiogenesis are often associated,27 and
the results suggested that aganirsen could have a dual
action on corneal neovascularization.
Several reasons could explain why vision may not have
been affected in this study, whereas vascular progression/
regression was signiﬁcantly changed. First, vessels often
grow ﬁrst into the peripheral cornea and so are less likely to
affect vision. Second, the secondary changes, such as edema
caused by neovessel edema, are unpredictable. Third, there
was a great variability in the included disease populations
with only limited knowledge on their natural disease course.
In terms of the other secondary end points, aganirsen
tended to decrease the need for transplantation in the overall
ITT population as assessed by the investigators, although
this reduction was not signiﬁcant (P ¼ 0.515). However,
when analyses were performed on patients combining
both viral keratitis and central neovascularization, aganirsen
signiﬁcantly decreased the need for transplantation,
although these results should be carefully interpreted
because of small sample sizes. This could indicate a more
favorable outcome in terms of need for transplantation with
aganirsen in patients with viral keratitis and central
Cursiefen et al  Aganirsen Inhibits Keratitis-Induced Corneal Neovascularizationneovascularization. Further research to conﬁrm these
encouraging results is warranted. Nonetheless, for the ﬁrst
time, the controlled study presented raises a new concept in
which the need for transplantation can be decreased by
combining an antiangiogenic therapy with a conventional
disease-speciﬁc (e.g., antiviral) therapy at the cornea.
However, this new concept of “primary prevention” needs
to be studied in greater detail in a more homogenous patient
population.
A large body of preclinical evidence suggests herpes
viruses to be a prime source of proangiogenic VEGF. In
addition, VEGF-mediated angiogenesis has been shown to
be an important part of the herpetic keratitis disease proc-
ess.28e30 In fact, in an animal model of viral keratitis,
antiangiogenic therapy could ameliorate the course of
herpetic keratitis disease.28 This in vivo evidence strongly
supports our new concept of antiangiogenic therapy in
combination with antiviral therapy in herpetic keratitis
being able to alter the disease course in a way that
positively affects the need for transplantation.
We did not observe any signiﬁcant reduction with aga-
nirsen in the assessment of the risk of graft rejection after
potential future transplantation. A possible explanation for
the lack of efﬁcacy on this end point could be that the “risk
of graft rejection” variable was evaluated using a 5-point
scale (very high, high, medium, low, very low/none),
whereas the “need for transplantation” variable was assessed
using a 3-point scale (high, medium, low). This difference
would increase the patients’ distribution for the “risk of graft
rejection” variable and would therefore make the aganirsen
effect less marked.
However, we found that the type of neovascularization
appeared to inﬂuence the risk of rejection, and this effect
was close to signiﬁcance (nominal P value ¼ 0.072). This
observation was consistent with a meta-analysis performed
on 19 studies: database analysis of 24,944 grafts showed
that graft failure and risk of rejection were increased with an
increasing number of corneal quadrants affected by neo-
vascularization before keratoplasty.7
In our study, the number of randomized patients (n ¼ 99)
was relatively low compared with the number of screened
patients (n ¼ 228): A total of 129 patients (56.6%) did not
meet the inclusion criteria and were excluded. These ex-
clusions probably resulted from the narrow inclusion
criteria. First, patients had to have keratitis for which the
treatment (including aganirsen) had been given orphan sta-
tus by European Regulatory Authorities.12 Second, patients
also had to demonstrate progression of neovascularization
within the timelines of the study to assess the effect of
aganirsen on an active rather than a quiescent corneal
neovascular process.
Current treatment of corneal graft rejection is based on
steroids and other immune-modulating agents, which are
associated with signiﬁcant side effects. In contrast, this
study showed that the safety and tolerability for aganirsen
eye drops were comparable to placebo. As such, aganirsen
has a promising role in reducing dependency on steroids
while signiﬁcantly improving the rate of success of corneal
grafts. Aganirsen has the potential to be the ﬁrst in its class
because there is currently no other trial-tested therapyavailable that delivers a speciﬁc topical antiangiogenic ef-
fect at the ocular surface and cornea.
In conclusion, the results of this ﬁrst phase III study on a
topical angiogenesis inhibitor of the ocular surface and
cornea showed that aganirsen eye drops signiﬁcantly
inhibited corneal neovascularization in patients with kera-
titis. The need for transplantation was signiﬁcantly
decreased in the small subgroup of patients with viral
keratitis and central corneal neovascularization. Further
studies focusing on these patients are necessary to support
and conﬁrm the novel concept in which the need for corneal
transplantation could be decreased by adding an anti-
angiogenic therapy to conventional antiviral therapy in
herpetic keratitis. Topical application of aganirsen was safe
and well tolerated.
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